Kejun Pharma Secures Over RMB 100 Million in Series B+ Financing to Accelerate Global Expansion

VCBeat has learned that on May 20, CureGene Pharmaceutical Co., Ltd. (hereinafter referred to as “CureGene”) announced the completion of its entire B+ round financing, exceeding RMB 100 million. This round follows the joint investment by Guoxin Innovation Equity, Yian Group, Infinity Capital, and Honghai Capital in September 2024. The current financing round was led byGuangdong Technology Financial Fund of FundsCapital Injection.

The proceeds from this financing round willPrimaryFor advancing core products in the cardiovascular and cerebrovascular fieldsof CG-0255Phase IIIClinical Development. Previously, CureGene had already garnered long-term favor from multiple well-known industry institutions, including Tailong Investment, Hankang Capital, and Yonghua Investment.

Since its establishment in Zhangjiang, Shanghai in 2018, CureGene has built upA Globally Leading R&D Technology Platform for Targeted Prodrugs and Antiviral Drugs, focusing on the research and development of innovative drugs with global competitiveness. The pipeline in development includes multiple innovative drugs with independent global intellectual property rights and significant market potential. CG-0255, a next-generation antiplatelet drug independently developed by CureGene, is an innovative platelet P2Y12 receptor antagonist that adopts a newly designed metabolic pathway. Clinical data have demonstrated its best-in-class potential.

CG-0255 has completed Phase II clinical trials in the United States for both injectable and oral formulations.Phase clinical trials, with related achievements successivelyInvited for presentation at the 2023 American Heart Association (AHA) Scientific Sessions and the 2024 European Society of Cardiology (ESC) Congress. Currently,The drug is being launched in the United States. Phase III clinical trials have also received the clinical trial approval from China’s Center for Drug Evaluation (CDE) and completed the clinical bridging study, marking a significant milestone in achieving synchronized clinical development in both China and the United States.

In the field of cardiovascular, cerebrovascular, and metabolic diseases,CureGene's Independently DevelopedFor metabolic liver disease/weight loss indicationsThe liver-targeted innovative drug CG-0416 has also entered the preclinical research stage, and separatelyIn2025 Asia-Pacific Association for the Study of LiverAnnual Conference (APASL2025）presented at the Annual Meeting of the European Association for the Study of the Liver (EASL 2025)The latest preclinical data have garnered widespread attention. Metabolic liver disease (formerly known as non-alcoholic fatty liver disease) has long posed a challenging problem for the global pharmaceutical industry. The CureGene team, leveraging its proprietaryNovel Hydrolyzable Prodrugs Developed via the Targeted Prodrug Technology PlatformCG-0416 is poised to address this unmet clinical need, providing patients with a safer and more effective therapeutic option.. Meanwhile, the latest published data show that CG-0416 in combination withGLP-1/GIP dual agonists demonstrate excellent synergistic benefits, offering the potential for superior lipid-lowering and weight-loss efficacy while significantly improving muscle preservation and enhancing lipid regulation, thereby holding substantial market potential.

Meanwhile, CureGene’s long-term commitment to the antiviral field continues to yield R&D breakthroughs, including multiple pipeline products such as broad-spectrum respiratory antiviral drugs and immunomodulators aimed at achieving a functional cure for chronic hepatitis B.All have achieved breakthrough progress, demonstrating broad prospects for clinical application. The company’s founder, Dr. He Gongxin, has overWith 30 years of experience in innovative drug R&D and industrialization, the individual has participated in and led the development of multiple international best-in-class new drugs, serving as a key inventor and project leader for several global blockbuster products currently on the market. The company’s core scientific and operational management team members all hail from world-renowned multinational pharmaceutical companies, bringing extensive expertise in innovative drug R&D, clinical operations, and industrialization across therapeutic areas including cardiovascular and cerebrovascular diseases, metabolism, respiratory disorders, and antiviral therapies.

Dr. He, founder of CureGene, stated:We sincerely thank investors from all sectors for their trust and support in CureGene’s innovative pipeline. This round of financing not only validates the capital market’s confidence in “Global Innovative Drug R&D CapabilitiesThis reflects strong recognition of the dual-wheel strategy driven by “China’s Intelligent Manufacturing Industrialization Advantages,” and further demonstrates the unique value derived from the synergistic development of our innovation engine and intelligent manufacturing capabilities. The funds raised will be primarily invested in the clinical development of core products in both China and the United States, while simultaneously advancing the global deployment of our innovative pipeline to accelerate the establishment of an internationally competitive R&D portfolio.

As a China-based, globally oriented innovator in biopharmaceuticals, CureGene remains dedicated to the independent research and development of breakthrough innovative drugs, committed to addressing unmet clinical needs worldwide. We look forward to deepening collaboration with global strategic partners and investment institutions to jointly build a value ecosystem spanning the entire lifecycle of R&D, clinical development, and commercialization, continuously creating hope for patients and contributing innovative expertise to the industry.

Guo Lining, Investment Director of Guangdong Technology Financial Fund of Funds, stated:As a highly innovative and promising enterprise in the pharmaceutical sector, CureGene has always been committed to contributing to the cause of human health. From the arduous explorations in the early stages of R&D to its current emergence as a notable player in pharmaceutical research and development, CureGene has earned widespread market recognition by leveraging its exceptional scientific research team and globally leading prodrug technology platform. The success of this financing round not only affirms CureGene’s past efforts but also injects strong momentum into its future development.

For investors, choosing to invest in CureGene was a decision marked by significant foresight and strategic vision. Amidst increasingly fierce competition and a complex, ever-changing market environment in the pharmaceutical industry, they identified the substantial value and growth potential inherent in CureGene, courageously injecting capital to accelerate its progress on the path of pharmaceutical innovation. The trust and support from investors have been the key driving force enabling CureGene to continuously break through barriers and achieve leapfrog development.As a partner of CureGene, Guangdong Technology Financial Fund of Funds has consistently monitored its development with great attention and remains confident in its future. We believe that CureGene will undoubtedly achieve greater brilliance in the pharmaceutical sector.

CureGene was established inIn 2018, it possessed core platform technologies and efficient, independent innovation capabilities. The company is currently primarily focused on cardiovascular, cerebrovascular, and metabolic diseases.In therapeutic areas such as oncology and antiviral treatments, CureGene is committed to becoming an innovative pharmaceutical company rooted in China with a global footprint. Leveraging its proprietary platform technologies, CureGene has successfully developed multiple innovative drug candidates with broad market value and independent global intellectual property rights, and is actively advancing the clinical development of several pipelines. Driven by its mission and vision, CureGene has assembled a team of high-caliber scientists and overseas-returnee talents with a global perspective. Under the company’s comprehensive strategic layout, CureGene has achieved rapid and efficient translation of R&D outcomes, with all pipeline candidates possessing the potential to becomeThe potential of First-in-Class or Best-in-Class drugs.

Guangdong Technology Financial Fund of Funds Management Co., Ltd.Established in August 2014 with a registered capital of RMB 100 million, Guangdong Technology Financial Fund of Funds Management Co., Ltd. is a wholly-owned fund management subsidiary of Guangdong Technology Financial Group. As the largest specialized state-owned fund of funds (FoF) investment and management platform in Guangdong Province and one of only five such specialized state-owned FoF management companies in China, it has been recognized among the world’s most promising FoFs and ranked among the top ten FoF management institutions in China. Serving as the primary vehicle for Guangdong Technology Financial Group to secure policy-based funding and leverage social capital, the company establishes and manages various types of funds, including government guidance funds, market-oriented FoFs, and strategic emerging industry funds. It oversees a cluster of 115 funds, including the Guangdong Provincial Innovation and Entrepreneurship Fund, the Yueke Nanhai FoF, and the Zhongshan Talent FoF, with a total asset under management exceeding RMB 80 billion. By leveraging social capital to amplify fiscal funds by nearly tenfold, the company promotes a virtuous cycle of “technology + finance + industry.”